Japanese delay for mogamulizumab in first line ATL

Save

A submission seeking approval of the CCR4-targeting antibody in untreated CCR4-positive adult T-cell leukemia-lymphoma (ATL) was made last July, but following discussions with the country's regulatory authority, the PMDA, Kyowa Kirin "has determined that…